Breast cancer histopathology image analysis pipeline for tumor purity estimation

Vahid Azimi, Young Hwan Chang, Guillaume Thibault, Jaclyn Smith, Takahiro Tsujikawa, Benjamin Kukull, Bradden Jensen, Christopher Corless, Adam Margolin, Joe Gray

Research output: Chapter in Book/Report/Conference proceedingConference contribution

1 Citation (Scopus)

Abstract

The translation of genomic sequencing technology to the clinic has greatly advanced personalized medicine. However, the presence of normal cells in tumors is a confounding factor in genome sequence analysis. Tumor purity, or the percentage of cancerous cells in whole tissue section, is a correction factor that can be used to improve the clinical utility of genomic sequencing. Currently, tumor purity is estimated visually by expert pathologists; however, it has been shown that there exist vast inter-observer discrepancies in tumor purity scoring. In this paper, we propose a quantitative image analysis pipeline for tumor purity estimation and provide a systematic comparison between pathologists' scores and our image-based tumor purity estimation.

Original languageEnglish (US)
Title of host publication2017 IEEE 14th International Symposium on Biomedical Imaging, ISBI 2017
PublisherIEEE Computer Society
Pages1137-1140
Number of pages4
ISBN (Electronic)9781509011711
DOIs
StatePublished - Jun 15 2017
Event14th IEEE International Symposium on Biomedical Imaging, ISBI 2017 - Melbourne, Australia
Duration: Apr 18 2017Apr 21 2017

Other

Other14th IEEE International Symposium on Biomedical Imaging, ISBI 2017
CountryAustralia
CityMelbourne
Period4/18/174/21/17

Fingerprint

Image analysis
Tumors
Pipelines
Breast Neoplasms
Neoplasms
Precision Medicine
Medicine
Sequence Analysis
Genes
Genome
Tissue
Technology
Pathologists

Keywords

  • Histopathology
  • Quantitative Image Analysis

ASJC Scopus subject areas

  • Biomedical Engineering
  • Radiology Nuclear Medicine and imaging

Cite this

Azimi, V., Chang, Y. H., Thibault, G., Smith, J., Tsujikawa, T., Kukull, B., ... Gray, J. (2017). Breast cancer histopathology image analysis pipeline for tumor purity estimation. In 2017 IEEE 14th International Symposium on Biomedical Imaging, ISBI 2017 (pp. 1137-1140). [7950717] IEEE Computer Society. https://doi.org/10.1109/ISBI.2017.7950717

Breast cancer histopathology image analysis pipeline for tumor purity estimation. / Azimi, Vahid; Chang, Young Hwan; Thibault, Guillaume; Smith, Jaclyn; Tsujikawa, Takahiro; Kukull, Benjamin; Jensen, Bradden; Corless, Christopher; Margolin, Adam; Gray, Joe.

2017 IEEE 14th International Symposium on Biomedical Imaging, ISBI 2017. IEEE Computer Society, 2017. p. 1137-1140 7950717.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Azimi, V, Chang, YH, Thibault, G, Smith, J, Tsujikawa, T, Kukull, B, Jensen, B, Corless, C, Margolin, A & Gray, J 2017, Breast cancer histopathology image analysis pipeline for tumor purity estimation. in 2017 IEEE 14th International Symposium on Biomedical Imaging, ISBI 2017., 7950717, IEEE Computer Society, pp. 1137-1140, 14th IEEE International Symposium on Biomedical Imaging, ISBI 2017, Melbourne, Australia, 4/18/17. https://doi.org/10.1109/ISBI.2017.7950717
Azimi V, Chang YH, Thibault G, Smith J, Tsujikawa T, Kukull B et al. Breast cancer histopathology image analysis pipeline for tumor purity estimation. In 2017 IEEE 14th International Symposium on Biomedical Imaging, ISBI 2017. IEEE Computer Society. 2017. p. 1137-1140. 7950717 https://doi.org/10.1109/ISBI.2017.7950717
Azimi, Vahid ; Chang, Young Hwan ; Thibault, Guillaume ; Smith, Jaclyn ; Tsujikawa, Takahiro ; Kukull, Benjamin ; Jensen, Bradden ; Corless, Christopher ; Margolin, Adam ; Gray, Joe. / Breast cancer histopathology image analysis pipeline for tumor purity estimation. 2017 IEEE 14th International Symposium on Biomedical Imaging, ISBI 2017. IEEE Computer Society, 2017. pp. 1137-1140
@inproceedings{d428c3c045b94858b8c50425ddac0f54,
title = "Breast cancer histopathology image analysis pipeline for tumor purity estimation",
abstract = "The translation of genomic sequencing technology to the clinic has greatly advanced personalized medicine. However, the presence of normal cells in tumors is a confounding factor in genome sequence analysis. Tumor purity, or the percentage of cancerous cells in whole tissue section, is a correction factor that can be used to improve the clinical utility of genomic sequencing. Currently, tumor purity is estimated visually by expert pathologists; however, it has been shown that there exist vast inter-observer discrepancies in tumor purity scoring. In this paper, we propose a quantitative image analysis pipeline for tumor purity estimation and provide a systematic comparison between pathologists' scores and our image-based tumor purity estimation.",
keywords = "Histopathology, Quantitative Image Analysis",
author = "Vahid Azimi and Chang, {Young Hwan} and Guillaume Thibault and Jaclyn Smith and Takahiro Tsujikawa and Benjamin Kukull and Bradden Jensen and Christopher Corless and Adam Margolin and Joe Gray",
year = "2017",
month = "6",
day = "15",
doi = "10.1109/ISBI.2017.7950717",
language = "English (US)",
pages = "1137--1140",
booktitle = "2017 IEEE 14th International Symposium on Biomedical Imaging, ISBI 2017",
publisher = "IEEE Computer Society",

}

TY - GEN

T1 - Breast cancer histopathology image analysis pipeline for tumor purity estimation

AU - Azimi, Vahid

AU - Chang, Young Hwan

AU - Thibault, Guillaume

AU - Smith, Jaclyn

AU - Tsujikawa, Takahiro

AU - Kukull, Benjamin

AU - Jensen, Bradden

AU - Corless, Christopher

AU - Margolin, Adam

AU - Gray, Joe

PY - 2017/6/15

Y1 - 2017/6/15

N2 - The translation of genomic sequencing technology to the clinic has greatly advanced personalized medicine. However, the presence of normal cells in tumors is a confounding factor in genome sequence analysis. Tumor purity, or the percentage of cancerous cells in whole tissue section, is a correction factor that can be used to improve the clinical utility of genomic sequencing. Currently, tumor purity is estimated visually by expert pathologists; however, it has been shown that there exist vast inter-observer discrepancies in tumor purity scoring. In this paper, we propose a quantitative image analysis pipeline for tumor purity estimation and provide a systematic comparison between pathologists' scores and our image-based tumor purity estimation.

AB - The translation of genomic sequencing technology to the clinic has greatly advanced personalized medicine. However, the presence of normal cells in tumors is a confounding factor in genome sequence analysis. Tumor purity, or the percentage of cancerous cells in whole tissue section, is a correction factor that can be used to improve the clinical utility of genomic sequencing. Currently, tumor purity is estimated visually by expert pathologists; however, it has been shown that there exist vast inter-observer discrepancies in tumor purity scoring. In this paper, we propose a quantitative image analysis pipeline for tumor purity estimation and provide a systematic comparison between pathologists' scores and our image-based tumor purity estimation.

KW - Histopathology

KW - Quantitative Image Analysis

UR - http://www.scopus.com/inward/record.url?scp=85023207013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023207013&partnerID=8YFLogxK

U2 - 10.1109/ISBI.2017.7950717

DO - 10.1109/ISBI.2017.7950717

M3 - Conference contribution

AN - SCOPUS:85023207013

SP - 1137

EP - 1140

BT - 2017 IEEE 14th International Symposium on Biomedical Imaging, ISBI 2017

PB - IEEE Computer Society

ER -